title: Imatinib discontinuation: realistic for patients with chronic myeloid leukaemia achieving complete molecular remission?
authors.forename: Fabio
authors.initials: F
authors.lastname: Stagno
authors.forename: Paolo
authors.initials: P
authors.lastname: Vigneri
authors.forename: Francesco
authors.initials: F
authors.lastname: Di Raimondo
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001549:Benzamides; D006801:Humans; D000068877:Imatinib Mesylate; D015477:Leukemia, Myelomonocytic, Chronic / Q000188:drug therapy*; D010879:Piperazines / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*; D012074:Remission Induction
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate